Matching articles for "lesinurad"
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • March 11, 2019; (Issue 1567)
Drugs for gout reduce the pain and inflammation of
acute flares and lower serum urate levels in order to
prevent recurrent flares, development of tophi, and
joint...
Drugs for gout reduce the pain and inflammation of
acute flares and lower serum urate levels in order to
prevent recurrent flares, development of tophi, and
joint damage.
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • November 6, 2017; (Issue 1533)
The FDA has approved Duzallo (Ironwood), a fixed-dose
combination of the uric acid transporter 1
(URAT1) inhibitor lesinurad (Zurampic) and the
xanthine oxidase inhibitor allopurinol (Zyloprim,...
The FDA has approved Duzallo (Ironwood), a fixed-dose
combination of the uric acid transporter 1
(URAT1) inhibitor lesinurad (Zurampic) and the
xanthine oxidase inhibitor allopurinol (Zyloprim, and
generics), for once-daily treatment of gout-associated
hyperuricemia in patients who have not achieved
target serum uric acid levels with allopurinol alone.
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • November 21, 2016; (Issue 1508)
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail...
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine oxidase
inhibitor monotherapy.